Department of Surgery, Zhejiang Hospital, Hangzhou, China.
Department of Health Management, Sir Run Run Shaw International Medical Centre, Hangzhou, China.
Medicine (Baltimore). 2022 Sep 9;101(36):e30559. doi: 10.1097/MD.0000000000030559.
The sex-determining region Y-box 2 (SOX2) has been identified to be involved in tumor progression and prognosis in patients with gastric cancer (GC). However, its action is paradoxical. Thus, we conducted the first meta-analysis based on eligible studies to evaluate the clinical utility of SOX2 in GC only.
A thorough electronic search was performed to collect eligible studies. The hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were generated from included studies to assess the strength of the association between SOX2 and prognosis and clinicopathological characteristics in GC.
A total of 10 studies comprising 1321 patients with GC were identified for the meta-analysis. The pooled results revealed that high SOX2 expression was significantly associated with poor overall survival compared to low SOX2 expression (pooled HR = 1.485; 95% CI: 1.022-2.160; 𝑃 = .04). The statistical significance between SOX2 expression and overall survival was also established in univariate analysis (pooled HR = 1.606; 95% CI: 1.134-2.274; 𝑃 < .01), as well as recruitment time exceeding 2010 (pooled HR = 1.873; 95% CI: 1.041-3.371; 𝑃 = .04), follow-up time more than 5 years (pooled HR = 1.642; 95% CI: 1.066-2.527; 𝑃 = .02), and cutoff value of more than 5% of cells stained (pooled HR = 1.730; 95% CI: 1.162-2.577; 𝑃 < .01). Moreover, we verified that positive SOX2 expression was correlated with advanced tumor invasion depth (pooled OR = 0.494; 95% CI: 0.362-0.675; 𝑃 < .01) and positive vascular invasion (pooled OR = 1.515; 95% CI: 1.078-2.130; 𝑃 = .02).
SOX2 could not only be an independent prognostic marker in GC but might also be a novel target for cancer therapy.
性决定区 Y 框 2（SOX2）已被确定参与胃癌（GC）患者的肿瘤进展和预后。然而，它的作用是矛盾的。因此，我们进行了首次基于合格研究的荟萃分析，仅评估 SOX2 在 GC 中的临床效用。
进行全面的电子搜索以收集合格的研究。从纳入的研究中生成风险比（HRs）或比值比（ORs）及其 95%置信区间（CIs），以评估 SOX2 与 GC 中预后和临床病理特征之间的关联强度。
共纳入了 10 项包含 1321 例 GC 患者的研究进行荟萃分析。汇总结果表明，与低 SOX2 表达相比，高 SOX2 表达与总生存率较差显著相关（合并 HR=1.485；95%CI：1.022-2.160；P=0.04）。SOX2 表达与总生存率之间的统计学意义也在单变量分析中得到证实（合并 HR=1.606；95%CI：1.134-2.274；P<0.01），以及入组时间超过 2010 年（合并 HR=1.873；95%CI：1.041-3.371；P=0.04）、随访时间超过 5 年（合并 HR=1.642；95%CI：1.066-2.527；P=0.02）和染色细胞比例超过 5%的截止值（合并 HR=1.730；95%CI：1.162-2.577；P<0.01）。此外，我们验证了阳性 SOX2 表达与肿瘤侵袭深度较深（合并 OR=0.494；95%CI：0.362-0.675；P<0.01）和血管侵犯阳性（合并 OR=1.515；95%CI：1.078-2.130；P=0.02）相关。
SOX2 不仅可以作为 GC 的独立预后标志物，而且可能成为癌症治疗的新靶点。
